75 completed, 8 withdrawn, 5 recruiting, 5 terminated. 95 Phase 1, 27 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 95 | Completed 75, Withdrawn 8, Recruiting 5, Terminated 5, Unknown 2 |
| Phase 2 | 27 | Completed 20, Terminated 3, Withdrawn 3, Recruiting 1 |
Follow Tobacco Use Disorder: new trials by email Literature Review of Tobacco Use Disorder trials Research Report on Tobacco Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g) - Thromboangiitis Obliterans (Buerger's Disease) | Phase 1 | Recruiting | Antidote Therapeutics, Inc | 15 | 2025-10-01 | 2025-10-15 |
| Effects of Cannabidiol on Stress and Nicotine Withdrawal Epidiolex - CBD, Stress | Phase 1 | Recruiting | Johns Hopkins University | 90 | 2025-08-25 | 2026-08-10 |
| Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors quitSTART Mobile Application, Chatbot Feature in quitSTART Mobile Application - Nicotine Vaping, Nicotine Use Disorder | Phase 1 | Terminated | Washington University School of Medicine | 26 | 2025-06-04 | 2026-10-26 |
| Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine (S)-Nicotine, (R)- nicotine, Racemic nicotine - Nicotine Dependence, Nicotine Vaping | Phase 1 | Recruiting | University of California, San Francisco | 18 | 2024-12-06 | 2026-05-14 |
| Overcoming Nicotine Dependence to Enable Quitting Nicotine Replacement Therapy (NRT) Sampling, Practice Quitting (PQ) Counseling, Motivational Interviewing (MI) Counseling - Tobacco Use, Smoking Cessation | Phase 1 / Phase 2 | Recruiting | Rush University Medical Center | 780 | 2023-03-24 | 2026-09-09 |
| Effects of E-cigarette Flavors on Youth TCORS 2.0 Flavoring Agents, Nicotine - Nicotine Use Disorder | Phase 1 | Completed | Yale University | 42 | 2022-11-07 | 2024-08-09 |
| Oral Cannabidiol for Tobacco Cessation 300 mg Cannabidiol, 600 mg Cannabidiol, Placebo - Tobacco Use, Tobacco Smoking | Phase 1 | Recruiting | Johns Hopkins University | 50 | 2022-11-01 | 2026-01-07 |
| Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers Nicotine, Cigarette - Nicotine Withdrawal, Nicotine Addiction | Phase 1 | Completed | Johns Hopkins University | 71 | 2022-07-27 | 2026-07-23 |
| Effects of Menthol in E-cigarettes on Smoking Behaviors Nicotine - Nicotine Dependence | Phase 1 | Completed | Yale University | 14 | 2022-05-10 | 2026-06-16 |
| Adaptive Treatment Strategies for Improving Engagement With a Web-Based Smoking Intervention in Socially Anxious Smokers Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages, Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages, Phase 2: re-engagement text messages - Social Anxiety Disorder, Tobacco Use Disorder | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2022-04-15 | 2021-12-08 | |
| Nicotine Differences in Smokers 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine, Saline - Nicotine Dependence | Phase 1 | Completed | Yale University | 11 | 2022-02-16 | 2023-12-11 |
| CO Monitoring for Tobacco Cessation in Quitlines Quitline Treatment as Usual (TAU), Remote Carbon Monoxide (CO) Monitoring, Incentivized Remote CO Monitoring - Tobacco Dependence | Phase 1 / Phase 2 | Completed | Consumer Wellness Solutions | 229 | 2021-12-31 | 2024-10-28 |
| A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza) - Tobacco Use Disorder | Phase 1 | Completed | HALEON | 22 | 2021-09-01 | 2024-03-21 |
| Study of EMB-001 as a Potential Smoking Cessation Treatment EMB-001 - Tobacco Use Disorder | Phase 1 / Phase 2 | Terminated | Embera NeuroTherapeutics, Inc. | 13 | 2021-06-10 | 2026-11-05 |
| The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence E-cigarettes - Nicotine Dependence | Phase 1 / Phase 2 | Completed | Duke University | 20 | 2021-05-21 | 2024-02-21 |
| Development of a mHealth Intervention for Ambivalent Smokers Control mHealth program, Experimental mHealth program, Nicotine patch - Tobacco Use Disorder, Smoking Cessation | Phase 1 | Completed | Kaiser Permanente | 57 | 2020-12-16 | 2023-01-23 |
| The Interaction of Flavor With Nicotine Form in Adult Smokers Nicotine form, E-cigarette experimental flavor - Nicotine Dependence | Phase 1 | Completed | Yale University | 20 | 2020-11-01 | 2023-05-26 |
| Flexiquit+: Web Program to Promote Smoking Cessation in Sexual and Gender Minority Young Adult Smokers Computer-Assisted Smoking Cessation Intervention, Text Message, Handout - Tobacco Use Disorder | Phase 1 | Completed | Fred Hutchinson Cancer Center | 25 | 2020-05-18 | 2020-10-05 |
| Brain Imaging in Tobacco Smokers During a Quit Attempt [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide), Contingency Management - Tobacco Use Disorder, Tobacco Smoking | Phase 1 | Completed | Johns Hopkins University | 15 | 2019-12-16 | 2024-08-06 |
| Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco Very Low Nicotine Content Cigarettes, Normal Nicotine Content Cigarettes - Nicotine Dependence, Cigarettes, Uncomplicated | Phase 1 / Phase 2 | Completed | Brown University | 57 | 2019-10-10 | 2023-12-19 |
Showing 20 of 95. Sign in to see all of them.
Smoking (23) · Smoking Cessation (17) · Tobacco Use (9) · Substance-Related Disorders (8) · Alcoholism (6) · Cigarette Smoking (5) · Vaping (5) · Marijuana Abuse (3) · Tobacco Smoking (3) · Tobacco Use Cessation (3) · Body Weight (2) · Acquired Immunodeficiency Syndrome (1) · Alcohol Drinking (1) · Amphetamine-Related Disorders (1)
Chemically-Induced Disorders (95) · Mental Disorders (94) · Substance-Related Disorders (87) · Behavior (53) · Health Behavior (20) · Smoking (12) · Tobacco Use (7) · Alcohol-Related Disorders (6) · Tobacco Smoking (5) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (3) · Narcotic-Related Disorders (2) · Anxiety Disorders (1) · Arterial Occlusive Diseases (1) · Bipolar and Related Disorders (1)
Nicotine (15) · Tobacco Use Cessation Devices (7) · Varenicline (6) · Bupropion (4) · Nicotine Replacement Therapy (3) · Behavior Therapy (2) · Cannabidiol (2) · Counseling (2) · Flavoring Agents (2) · Memantine (2) · Menthol (2) · Naltrexone (2) · Sodium Chloride (2) · Sugars (2) · histaminol (2)
Yale University (17) · National Institute on Drug Abuse (NIDA) (8) · Johns Hopkins University (5) · Boston Children's Hospital (4) · Duke University (4) · Pierre Fabre Medicament (4) · GlaxoSmithKline (3) · McNeil AB (3) · Mclean Hospital (3) · New York State Psychiatric Institute (3) · Star Scientific, Inc (3) · University of Vermont (3) · Brown University (2) · Embera NeuroTherapeutics, Inc. (2) · Fred Hutchinson Cancer Center (2)
United States (84) · France (4) · China (2) · Canada (1) · Germany (1) · Russia (1) · Spain (1) · Sweden (1)
Maria Varga, MD (5) · Adam Bisaga, M.D. (2) · John R. Knight, MD (2) · Stephen T. Higgins, Ph.D. (2) · Albert Arias, MD (1) · Amanda Mathew, PhD (1) · Amy Janes, PhD (1) · Andrea H. Weinberger, Ph.D. (1) · Annie Umbricht, M.D. (1) · Arthur L. Brody, MD (1) · Benjamin A Toll, Ph.D. (1) · Benjamin A. Toll, Ph.D. (1) · Benjamin A. Toll, PhD (1) · Benjamin Toll, Ph.D. (1)
PMID 32628945, PMID 33079196, PMID 34242666, PMID 34255068, PMID 36208817, PMID 38236223, PMID 42560883, PMID 33605440, PMID 17587504, PMID 20056957, PMID 22160487, PMID 22452559, PMID 24821356, PMID 25118794, PMID 25419583, PMID 26476459, PMID 27215559, PMID 27852796, PMID 32297782, PMID 33140460, PMID 34347865, PMID 37142273, PMID 37379059, PMID 39665506, PMID 39834135, PMID 40489161, PMID 40623557
U54DA036151 (4), P50DA036114 (3), P50AA015632 (2), R01DA017572 (2), 271201400069C-0-0-1 (1), 271201500019C-0-0-1 (1), K01DA051882 (1), K23AA020000 (1), K23DA025049 (1), K23DA048181 (1), N01CN35159 (1), P30CA015704 (1), R00DA037276 (1), R01CA140256 (1), R01DA008075 (1)